Biography
Dr. Mohile completed his residency training at Northwestern University, followed by a fellowship in neuro-oncology at Memorial Sloan-Kettering Cancer Center. He is certified in Neurology and Neuro-oncology. In 2007, he joined the neurology department at the University of Rochester where he built and fostered the neuro-oncology division and multi-disciplinary brain tumor program. His mission is to teach, elevate clinical care and perform research that extends and improves the lives of patients with brain tumors.
Dr. Mohile sees patients with primary and metastatic brain tumors and is involved in administering chemotherapy, treating seizures and managing side effects of brain tumors and brain tumor therapy. In addition, he does consultations on patients with neurologic complications of cancer or cancer treatments.
Professional Background
Nimish Mohile, MD, MS, FAAN is an Associate Professor of Neurology and Oncology at the University of Rochester and the Ann Aresty Camhi Professor of Neurology. He serves as the Associate Chair for Career Development and Leadership, Neuro-oncology Division Chief and Leader of the Neuro-oncology service line. He is a UCNS fellowship program director, serves on the UCNS Certification committee, chairs the American Society of Clinical Oncology Glioma Guidelines Panel and is currently the Vice-chair of the AAN section for Neuro-oncology.
As an Associate Chair for Career Development and Leadership, he has spearheaded innovative programs that emphasize personal values, identity and reflective work in the professional development of faculty, administrative staff, advanced practice providers and residents. He also directs departmental leadership programs for residents and faculty to develop leadership skills, implement change and develop resilient teams.
Dr. Mohile aspires to help organizations transform into multicultural, antiracist and equitable entities. He is an advocate for incorporating principles of inclusion, diversity, equity, antiracism and social justice into the profession of neurology. He serves as a diversity officer in the Department of Neurology at the University of Rochester, where he also chairs the Antiracism working group. He currently co-chairs the AAN Diversity Officer’s Group, is a member of the EDI Joint Coordinating Council and was recently appointed to the AAN Special Commission for Racism, Inequity and Social Justice.
Research
His research focuses on developing and testing therapeutic and supportive care interventions to improve and extend the lives of patients with malignant gliomas. He has authored over 50 peer-reviewed publications. He is currently the principal investigator of several industry-sponsored, investigator-initiated and NCI- funded clinical trials. He has developed a body of work that explores the burdens experienced by patients wtih brain tumors and caregivers, related to hospitalizations, seizures, decision-making and end of life care.
Awards
2015
A. B. Baker Teacher Recognition Award
Sponsor: American Academy of Neurology
2011
SWOG Travel Award Recipient
Sponsor: Southwest Oncology Group
2011
Neurology Faculty Teaching Award
Sponsor: University of Rochester
Location: Rochester, NY
2009
American Neurological Association Junior Academic Scholarship Award
2007
American Society of Clinical Oncology Foundation Merit Award
Sponsor: American Society of Clinical Oncology Foundation
2004
Graduate Medical Education Award for excellence in teaching medical students
2004
AAN Resident Annual Meeting Scholarship
Sponsor: American Academy of Neurology
1996 - 2000
Dean's List
Sponsor: St George's University
Location: Grenada, WI
1994
Dean's List
Sponsor: Duke University
Location: Durham, NC
VIEW ALL expand_more
Clinical Trials
A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy,A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Lead Researcher: Nimish A Mohile
This is an event driven, adaptive design, a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 3 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy.
View Study Details
A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy,A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy
Lead Researcher: Nimish A Mohile
This is a dose-escalation study of DSP-7888 Dosing Emulsion administered to adult patients with advanced malignancies. Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally (between the skin layers) or subcutaneously (under the skin) in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once every 7 to 14 days for 6 weeks during the Consolidation Phase, and once every 14 to 28 days until a discontinuation criterion is met during the Maintenance Phase.
Once the highest dose with acceptable toxicity is determined from either the intradermal or subcutaneous group, an additional 40 patients may be enrolled as an expansion cohort at this dose and route of administration to confirm safety and tolerability.
Separate from the dose-ascending cohort and expansion cohort described previously, and once the intradermal dose-ascending cohort is completed, up to 20 myelodysplastic syndrome (MDS) patients who are resistant to treatment with hypomethylating agents (HMAs) will be enrolled into an MDS expansion cohort. Of these 20 MDS patients, one-half will receive DSP-7888 at 10.5 mg according to the modified schedule employed in Phase 1 (every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks [Named MDS Cohort 1]). The other half of the MDS patients will receive DSP-7888 at 10.5 mg in an alternative dosing schedule where DSP-7888 is administered every 2 weeks until Week 24, after which it will be administered every 4 weeks (Named MDS Cohort 2).
View Study Details
Publications
Journal Articles
8/16/2021
Gelb DJ, Kraakevik J, Safdieh JE, Agarwal S, Odia Y, Govindarajan R, Quick A, Soni M, , Bickel J, Gamaldo C, Hannon P, Hatch HAM, Hernandez C, Merlin LR, Noble JM, Reyes-Iglesias Y, Marie E Salas R, Sandness DJ, Treat L, , Benameur K, Brown RD, DeLuca GC, Garg N, Goldstein LB, Gutmann L, Henchcliffe C, Hessler A, Jordan JT, Kilgore SM, Khan J, Levin KH, Mohile NA, Nevel KS, Roberts K, Said RR, Simpson EP, Sirven JI, Smith AG, Southerland AM, Wilson RB. "Contemporary Neuroscience Core Curriculum for Medical Schools." Neurology.. 2021 Aug 16; Epub 2021 Aug 16.
4/12/2021
Xu H, Kadambi S, Mohile SG, Yang S, Kehoe LA, Wells M, Culakova E, Kamen C, Obrecht S, Mohamed M, Gilmore NJ, Magnuson A, Grossman VA, Hopkins JO, Geer J, Berenberg J, Mustian K, Cupertino A, Mohile N, Loh KP. "Caregiving burden of informal caregivers of older adults with advanced cancer: The effects of rurality and education." Journal of geriatric oncology.. 2021 Apr 12; Epub 2021 Apr 12.
1/5/2021
Mohile NA, Spector AR, Ebong IM, Flippen C, Gutierrez C, Leacock RO, Marulanda-Londoño E, Mejia NI, Thomas R, Hamilton RH. "Developing the Neurology Diversity Officer: A Roadmap for Academic Neurology Departments." Neurology.. 2021 Jan 5; Epub 2021 Jan 05.
Books & Chapters
2007
Chapter Title: Principles of Chemotherapy
Book Title: Brain Tumors: Practical Guide to Diagnosis and Treatment
Author List: Abrey LE and Mohile NA
Edited By: Baehring J, Piepmeier J
Published By: Informa Health Care, USA 2007 in New York
2006
Chapter Title: Chemotherapy of Neuronal Tumors
Book Title: Handbook of Brain Tumor Chemotherapy
Author List: Mohile, N.A.; Raizer, J.J.
Edited By: Newton, H.B.
Published By: Elsevier 2006 in Amsterdam: Boston
VIEW ALL PUBLICATIONS